{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T04:29:31Z","timestamp":1787891371352,"version":"build-2784847793"},"reference-count":51,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Dermatology"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.clindermatol.2023.10.006","type":"journal-article","created":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T04:46:39Z","timestamp":1698727599000},"page":"9-16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Ocular and eyelid involvement in collagen vascular diseases. Part II. Dermatomyositis, scleroderma, and sarcoidosis"],"prefix":"10.1016","volume":"42","author":[{"given":"Sueheidi","family":"Santiago","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ndidi","family":"Enwereji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khayyam","family":"Durrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sona","family":"Chaudhry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clindermatol.2023.10.006_bib0001","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1111\/bjd.15607","article-title":"The pathogenesis of dermatomyositis","volume":"179","author":"Thompson","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2023.10.006_bib0002","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.clindermatol.2018.04.003","article-title":"Dermatomyositis: current concepts","volume":"36","author":"Bogdanov","year":"2018","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.clindermatol.2023.10.006_bib0003","first-page":"355","article-title":"Ophthalmic manifestations in paediatric practice","volume":"79","author":"Taylor","year":"1959","journal-title":"Trans Ophthalmol Soc UK"},{"key":"10.1016\/j.clindermatol.2023.10.006_bib0004","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1001\/archopht.1951.01700020443009","article-title":"Retinopathy in dermatomyositis","volume":"46","author":"De Vries","year":"1951","journal-title":"AMA Arch Ophthalmol"},{"key":"10.1016\/j.clindermatol.2023.10.006_bib0005","doi-asserted-by":"crossref","first-page":"E340","DOI":"10.1503\/cmaj.180947","article-title":"Dermatomyositis","volume":"191","author":"Chu","year":"2019","journal-title":"CMAJ"},{"key":"10.1016\/j.clindermatol.2023.10.006_bib0006","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1136\/bjo.43.9.548","article-title":"Fundus appearances in a case of acute dermatomyositis","volume":"43","author":"Munro","year":"1959","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.clindermatol.2023.10.006_bib0007","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/WNO.0000000000000235","article-title":"Dermatomyositis-related nonischemic central retinal vein occlusion","volume":"35","author":"Wang","year":"2015","journal-title":"J Neuro-Ophthalmol"},{"key":"10.1016\/j.clindermatol.2023.10.006_bib0008","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3109\/09273948.2010.531895","article-title":"Frosted branch angiitis, presumably related to dermatomyositis","volume":"19","author":"Lee","year":"2011","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.clindermatol.2023.10.006_bib0009","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1093\/rheumatology\/34.12.1179","article-title":"Irreversible visual loss in dermatomyositis","volume":"34","author":"Yeo","year":"1995","journal-title":"Rheumatology"},{"key":"10.1016\/j.clindermatol.2023.10.006_bib0010","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.rbr.2014.12.004","article-title":"Neuromielite \u00f3ptica em uma adolescente com dermatomiosite juvenil [Devic's disease in an adolescent girl with juvenile dermatomyositis]","volume":"57","author":"Fraga","year":"2017","journal-title":"Rev Bras Reumatol"},{"key":"10.1016\/j.clindermatol.2023.10.006_bib0011","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1365-2133.1994.tb08492.x","article-title":"Cutaneous photosensitivity in dermatomyositis","volume":"131","author":"Cheong","year":"1994","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2023.10.006_bib0012","first-page":"637","article-title":"Bilateral ocular myositis as a late complication of dermatomyositis","volume":"33","author":"Liu","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clindermatol.2023.10.006_bib0013","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s12016-017-8652-1","article-title":"Cutaneous manifestations of dermatomyositis: a comprehensive review","volume":"53","author":"Mainetti","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.clindermatol.2023.10.006_bib0014","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1136\/ard.57.8.447","article-title":"Ophthalmic manifestations of dermatomyositis","volume":"57","author":"Backhouse","year":"1998","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clindermatol.2023.10.006_bib0015","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1080\/14397595.2018.1467257","article-title":"Current diagnosis and treatment of polymyositis and dermatomyositis","volume":"28","author":"Sasaki","year":"2018","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.clindermatol.2023.10.006_bib0016","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jdcr.2021.01.035","article-title":"Lagophthalmos as a presenting sign in dermatomyositis with muscle involvement limited to the ocular muscles","volume":"10","author":"Roesler","year":"2021","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.clindermatol.2023.10.006_bib0017","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s00296-021-05035-7","article-title":"Polymyositis and dermatomyositis: ocular manifestations and potential sight-threatening complications","volume":"42","author":"Ruiz-Lozano","year":"2022","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.clindermatol.2023.10.006_bib0018","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jaad.2019.06.1309","article-title":"Dermatomyositis: clinical features and pathogenesis","volume":"82","author":"DeWane","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2023.10.006_bib0019","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1080\/09273948.2019.1657467","article-title":"A wide spectrum of ocular manifestations signify patients with systemic sclerosis","volume":"29","author":"Szucs","year":"2021","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.clindermatol.2023.10.006_bib0020","article-title":"Polymyositis and dermatomyositis\u2014challenges in diagnosis and management","volume":"2","author":"Yang","year":"2019","journal-title":"J Transl Autoimmun"},{"key":"10.1016\/j.clindermatol.2023.10.006_bib0021","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1136\/annrheumdis-2012-202794","article-title":"A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-\u03b1 monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients","volume":"73","author":"Higgs","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clindermatol.2023.10.006_bib0022","doi-asserted-by":"crossref","first-page":"9013","DOI":"10.1038\/s41598-017-08534-5","article-title":"Sodium hyaluronate in the treatment of dry eye syndrome: a systematic review and meta-analysis","volume":"7","author":"Ang","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.clindermatol.2023.10.006_bib0023","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.semarthrit.2018.12.007","article-title":"Ocular involvement in systemic sclerosis: a systematic literature review, it's not all scleroderma that meets the eye","volume":"49","author":"Kreps","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2023.10.006_bib0024","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.survophthal.2008.12.007","article-title":"Ocular manifestations of scleroderma","volume":"54","author":"Tailor","year":"2009","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.clindermatol.2023.10.006_bib0025","doi-asserted-by":"crossref","first-page":"15002","DOI":"10.1038\/nrdp.2015.2","article-title":"Systemic sclerosis","volume":"1","author":"Allanore","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.clindermatol.2023.10.006_bib0026","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.3899\/jrheum.101248","article-title":"Clinical and serological hallmarks of systemic sclerosis overlap syndromes","volume":"38","author":"Pakozdi","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clindermatol.2023.10.006_bib0027","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1136\/bjo.53.6.388","article-title":"Ophthalmic manifestations of progressive systemic sclerosis","volume":"53","author":"Horan","year":"1969","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.clindermatol.2023.10.006_bib0028","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.berh.2018.08.005","article-title":"Update on the epidemiology, risk factors, and disease outcomes of systemic sclerosis","volume":"32","author":"Ingegnoli","year":"2018","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.clindermatol.2023.10.006_bib0029","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/s12016-017-8625-4","article-title":"Cutaneous manifestations of scleroderma and scleroderma-like disorders: a comprehensive review","volume":"53","author":"Ferreli","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.clindermatol.2023.10.006_bib0030","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.cytogfr.2004.03.006","article-title":"Regulation of PDGF and its receptors in fibrotic diseases","volume":"15","author":"Bonner","year":"2004","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.clindermatol.2023.10.006_bib0031","doi-asserted-by":"crossref","first-page":"v2","DOI":"10.1093\/rheumatology\/ken265","article-title":"Role of PDGF in fibrotic diseases and systemic sclerosis","volume":"47","author":"Trojanowska","year":"2008","journal-title":"Rheumatology"},{"key":"10.1016\/j.clindermatol.2023.10.006_bib0032","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s10792-019-01183-9","article-title":"Ocular manifestations of rheumatic diseases","volume":"40","author":"Kemeny-Beke","year":"2020","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.clindermatol.2023.10.006_bib0033","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1590\/S1807-59322011000300003","article-title":"Ocular findings in patients with systemic sclerosis","volume":"66","author":"de AF Gomes","year":"2011","journal-title":"Clinics (Sao Paulo)"},{"key":"10.1016\/j.clindermatol.2023.10.006_bib0034","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1136\/bjo.63.12.845","article-title":"Ocular involvement in scleroderma","volume":"63","author":"West","year":"1979","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.clindermatol.2023.10.006_bib0035","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1136\/ard.2010.142000","article-title":"Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis","volume":"70","author":"Le","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clindermatol.2023.10.006_bib0036","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/art.11113","article-title":"The American College of Rheumatology Ad Hoc Committee on Immunologic Testing Guidelines. Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies","volume":"49","author":"Reveille","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2023.10.006_bib0037","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/1756-185X.13035","article-title":"Long-term efficacy and tolerability of mycophenolate mofetil therapy in diffuse scleroderma skin disease","volume":"20","author":"Boulos","year":"2017","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.clindermatol.2023.10.006_bib0038","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1093\/rheumatology\/kep295","article-title":"A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis","volume":"48","author":"Derk","year":"2009","journal-title":"Rheumatology"},{"key":"10.1016\/j.clindermatol.2023.10.006_bib0039","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.3899\/jrheum.111229","article-title":"A prospective observational study of mycophenolate mofetil treatment in progressive diffuse cutaneous systemic sclerosis of recent onset","volume":"39","author":"Mendoza","year":"2012","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clindermatol.2023.10.006_bib0040","unstructured":"Denton CP. Overview of the treatment and prognosis of systemic sclerosis (scleroderma) in adults. Available at: https:\/\/www.uptodate.com\/contents\/overview-of-the-treatment-and-prognosis-of-systemic-sclerosis-scleroderma-in-adults?search=pruritis%20scleroderma&source=search_result&selectedTitle=1\u223c150&usage_type=default&display_rank=1#H1. Accessed January 28, 2022."},{"key":"10.1016\/j.clindermatol.2023.10.006_bib0045","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/ar2977","article-title":"B-cell depletion with rituximab: a promising treatment for diffuse cutaneous systemic sclerosis","volume":"12","author":"van Laar","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.clindermatol.2023.10.006_bib0043","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/art.24249","article-title":"B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis","volume":"60","author":"Lafyatis","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2023.10.006_bib0044","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11926-010-0150-x","article-title":"B-cell\u2013targeted therapy for the fibrotic complications of systemic sclerosis","volume":"13","author":"Woodrick","year":"2011","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.clindermatol.2023.10.006_bib0046","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1136\/annrheumdis-2018-213031","article-title":"Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis","volume":"77","author":"Denton","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clindermatol.2023.10.006_bib0047","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2147\/OPTH.S128949","article-title":"Management of chronic ocular sarcoidosis: challenges and solutions","volume":"12","author":"Matsou","year":"2018","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.clindermatol.2023.10.006_bib0048","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/S0140-6736(04)17554-5","article-title":"The eye in systemic inflammatory diseases","volume":"364","author":"McCluskey","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.clindermatol.2023.10.006_bib0049","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.ccm.2015.08.009","article-title":"Ocular sarcoidosis","volume":"36","author":"Pasadhika","year":"2015","journal-title":"Clin Chest Med"},{"key":"10.1016\/j.clindermatol.2023.10.006_bib0050","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1055\/s-0040-1713130","article-title":"Cutaneous sarcoidosis","volume":"41","author":"Caplan","year":"2020","journal-title":"Semin Respir Crit Care Med"},{"key":"10.1016\/j.clindermatol.2023.10.006_bib0051","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1007\/s10792-020-01531-0","article-title":"Ocular sarcoidosis: clinical experience and recent pathogenetic and therapeutic advancements","volume":"40","author":"Dammacco","year":"2020","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.clindermatol.2023.10.006_bib0052","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3899\/jrheum.190768","article-title":"Ocular manifestations in rheumatoid arthritis, connective tissue disease, and vasculitis: a systematic review and metaanalysis","volume":"48","author":"Turk","year":"2021","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clindermatol.2023.10.006_bib0053","doi-asserted-by":"crossref","first-page":"20","DOI":"10.21037\/aes-20-80","article-title":"Biologics in non-infectious uveitis past, present and future","volume":"6","author":"Zaki","year":"2021","journal-title":"Ann Eye Sci"}],"container-title":["Clinics in Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X23001712?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X23001712?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:22:31Z","timestamp":1760034151000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0738081X23001712"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S0738081X23001712"],"URL":"https:\/\/doi.org\/10.1016\/j.clindermatol.2023.10.006","relation":{},"ISSN":["0738-081X"],"issn-type":[{"value":"0738-081X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ocular and eyelid involvement in collagen vascular diseases. Part II. Dermatomyositis, scleroderma, and sarcoidosis","name":"articletitle","label":"Article Title"},{"value":"Clinics in Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clindermatol.2023.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}